1. BRENTUXIMAB‐VEDOTIN AND BENDAMUSTINE IS A FEASIBLE AND EFFECTIVE DRUG COMBINATION AS FIRST‐LINE TREATMENT OF HODGKIN LYMPHOMA IN THE ELDERLY (HALO TRIAL). (12th June 2019) Authors: Gallamini, A.; Schiano de Colella, J.; Viotti, J.; Bijou, F.; Rambaldi, A.; Perrot, A.; Patti, C.; Gastaud, L.; Sorasio, R.; Debaigt, C.; Schiappa, R.; Chamorey, E.; Viviani, S.; Thyss, A. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 292 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. BRENTUXIMAB‐VEDOTIN AND BENDAMUSTINE IS A FEASIBLE AND EFFECTIVE DRUG COMBINATION AS FIRST‐LINE TREATMENT OF HODGKIN LYMPHOMA IN THE ELDERLY (HALO TRIAL). (June 2017) Authors: Gallamini, A.; Bijou, F.; Viotti, J.; Rossi, A.; Perrot, A.; Patti, C.; Gastaud, L.; Sorasio, R.; Debaigt, C.; Chamorey, E.; Viviani, S.; Thyss, A. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 170 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P555: A PHASE 1B/2 STUDY OF THE CD123-TARGETING ANTIBODY-DRUG CONJUGATE PIVEKIMAB SUNIRINE (IMGN632) IN COMBINATION WITH VENETOCLAX (VEN) AND AZACITIDINE (AZA) FOR PATIENTS WITH CD123-POSITIVE AML. (23rd June 2022) Authors: Daver, N. G.; Montesinos, P.; Aribi, A.; Martinelli, G.; Altman, J.; Roboz, G.; Wang, E. S.; Burke, P. W.; Jeyakumar, D.; Walter, R. B.; DeAngelo, D. J.; Erba, H. P.; Advani, A.; Gastaud, L.; Thomas, X.; Todisco, E.; Pemmaraju, N.; Mendez, L.; de la Fuente, A.; Gaidano, G. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 454 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. PB1805: INSIGHTS FROM ORAL AZACITIDINE EARLY ACCESS PROGRAM IN FRANCE: PATIENT POPULATION WITH ACUTE MYELOID LEUKEMIA RECEIVING ORAL-AZA FOR MAINTENANCE OF COMPLETE REMISSION AFTER INDUCTION CHEMOTHERAPY. (23rd June 2022) Authors: Raffoux, E.; De Botton, S.; Ades, L.; Carré, M.; Cluzeau, T.; Saillard, C.; Heiblig, M.; Beckerich, F.; Gastaud, L.; Dupuis, A.; Richez, U.; Dumas, P.-Y. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1685 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Meningeal SWI/SNF related, matrix‐associated, actin‐dependent regulator of chromatin, subfamily B member 1 (SMARCB1)‐deficient tumours: an emerging group of meningeal tumours. (28th December 2016) Authors: Dadone, B.; Fontaine, D.; Mondot, L.; Cristofari, G.; Jouvet, A.; Godfraind, C.; Varlet, P.; Ranchère‐Vince, D.; Coindre, J.‐M.; Gastaud, L.; Baudoin, C.; Peyron, A.‐C.; Thyss, A.; Coutts, M.; Michiels, J.‐F.; Pedeutour, F.; Burel‐Vandenbos, F. Journal: Neuropathology & applied neurobiology Issue: Volume 43:Number 5(2017) Page Start: 433 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Very Late Local Relapse of Ewing's Sarcoma of the Head and Neck treated with Aggressive Multimodal Therapy. (20th May 2008) Authors: Thariat, J.; Italiano, A.; Peyrade, F.; Birtwisle-Peyrottes, I.; Gastaud, L.; Dassonville, O.; Thyss, A. Other Names: Raut Chandrajit Academic Editor. Journal: Sarcoma Issue: Volume 2008(2008) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Very Late Local Relapse of Ewing's Sarcoma of the Head and Neck treated with Aggressive Multimodal Therapy. (20th May 2008) Authors: Thariat, J.; Italiano, A.; Peyrade, F.; Birtwisle-Peyrottes, I.; Gastaud, L.; Dassonville, O.; Thyss, A. Other Names: Raut Chandrajit Academic Editor. Journal: Sarcoma Issue: Volume 2008(2008) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Incidence of Orbital Exenteration: A Nationwide Study in France over the 2006-2017 Period. (4th March 2021) Authors: Martel, A.; Nahon-Esteve, S; Gastaud, L.; Bertolotto, C.; Lassalle, S.; Baillif, S.; Charles, A. Journal: Ophthalmic epidemiology Issue: Volume 28:Number 2(2021) Page Start: 169 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. 50 BCL2L10-POSITIVE CELL (BPC) QUANTIFICATION IS A PREDICTIVE FACTOR OF SURVIVAL IN AZA-TREATED HIGHER RISK MDS (HR-MDS) AND AML. (April 2015) Authors: Cluzeau, T.; Vidal, V.; Ginet, C.; Karsenti, J.M.; Luciano, F.; Gastaud, L.; Garnier, G.; Braun, T.; Hirsch, P.; Raffoux, E.; Nloga, A.M.; Dombret, H.; Rorhlich, P.; Ades, L.; Chomienne, C.; Auberger, P.; Robert, G.; Fenaux, P. Journal: Leukemia research Issue: Volume 39(2015:Apr.) Supplement 1 Page Start: S23 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Description of late onset neutropenia in indolent lymphoma patients treated with bendamustine plus rituximab. Issue 1 (7th July 2017) Authors: Verriere, B.; Gastaud, L.; Chamorey, E.; Peyrade, F.; Deletie, E.; Bouredji, K.; Quinsat, D.; Schiappa, R.; Thyss, A.; Re, D. Journal: Hematological oncology Issue: Volume 36:Issue 1(2018) Page Start: 144 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗